Most health plans are covering at least one of the two biosimilar products currently on the market, according to new research by the strategic advisory company Avalere.
A new study of physicians and health plan executives reveals some progress toward achieving value-based care, but indicates health information technology, such as electronic health records (EHRs) are still not bridging many critical gaps.
U.S. Speaker of the House Paul Ryan (R-WI) takes questions at a news conference in Washington, U.S. May 12, 2016. Reuters/Jim Bourg/Files U.S. House of Representatives Speaker Paul Ryan unveiled […]
Express Scripts Holding Co, the largest manager of prescription drug plans for U.S. employers and health plans, said it has reached deals to cover two costly new cholesterol drugs and […]